Damora Therapeutics, Inc.
General ticker "DMRA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.0B (TTM average)
Damora Therapeutics, Inc. follows the US Stock Market performance with the rate: 12.2%.
Estimated limits based on current volatility of 5.4%: low 21.92$, high 24.43$
Factors to consider:
- Current price 324.2% above estimated high
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.42$, 7.41$]
- 2025-12-31 to 2026-12-31 estimated range: [1.95$, 5.67$]
Short-term DMRA quotes
Long-term DMRA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $61.21MM | $36.46MM | $16.90MM |
| Operating Income | $-61.21MM | $-36.46MM | $-16.90MM |
| Non-Operating Income | $-0.42MM | $-1.89MM | $-4.50MM |
| R&D Expense | $48.21MM | $23.77MM | $6.40MM |
| Income(Loss) | $-61.62MM | $-38.35MM | $-21.40MM |
| Taxes | $0.00MM | $0.00MM | $0.04MM |
| Net Income(Loss)* | $-61.62MM | $-38.35MM | $-21.44MM |
| Stockholders Equity | $61.75MM | $32.33MM | $14.47MM |
| Assets | $73.19MM | $38.23MM | $17.13MM |
| Operating Cash Flow | $-42.93MM | $-36.91MM | $-18.62MM |
| Capital expenditure | $0.20MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $12.38MM | $22.33MM | $11.65MM |
| Financing Cash Flow | $0.51MM | $2.88MM | $0.00MM |
| Earnings Per Share** | $-60.63 | $-36.08 | $-18.53 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.